- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06251310
SW-682 i avanserte solide svulster
En fase 1a/1b doseeskalering, doseutvidelsesstudie av SW-682 hos deltakere med avanserte solide svulster beriket for de med mutasjoner i flodhestveien
This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: US Medical Information
- Telefonnummer: 888-275-7376
- E-post: eMediUSA@emdserono.com
Studiesteder
-
-
Arizona
-
Scottsdale, Arizona, Forente stater, 85258
- Rekruttering
- HonorHealth Research Institute
-
Hovedetterforsker:
- Muhammad R Khawaja, MD
-
Ta kontakt med:
- E-post: mkhawaja@honorhealth.com
-
-
California
-
Los Angeles, California, Forente stater, 90033
- Rekruttering
- USC Norris Comprehensive Cancer Center and Hospital
-
Hovedetterforsker:
- Diana Hanna, MD
-
Ta kontakt med:
- E-post: diana.hanna@med.usc.edu
-
Sacramento, California, Forente stater, 92093
- Rekruttering
- UC San Diego Moores Cancer Center
-
Hovedetterforsker:
- Sandip Patel, MD
-
Ta kontakt med:
- E-post: sandippatel@ucsd.edu
-
Santa Monica, California, Forente stater, 90404
- Rekruttering
- UCLA Hematology-Oncology - Santa Monica
-
Hovedetterforsker:
- Arun S Singh, MD
-
Ta kontakt med:
- E-post: Asingh@mednet.ucla.edu
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44106
- Rekruttering
- University Hospital of Cleveland
-
Hovedetterforsker:
- Afshin Dowlati, MD
-
Ta kontakt med:
- Telefonnummer: 216-844-3951
- E-post: afshin.dowlati@uhhospitals.org
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- Rekruttering
- Oregon Health and Science University, Knight Cancer Institute - Marquam Hill
-
Hovedetterforsker:
- Shivaani Kummar
-
Ta kontakt med:
- E-post: kummar@ohsu.edu
-
-
Texas
-
Dallas, Texas, Forente stater, 75230
- Rekruttering
- Mary Crowley Research Center US Oncology
-
Hovedetterforsker:
- Douglas Orr, MD
-
Ta kontakt med:
- Telefonnummer: 972-566-3000
- E-post: Douglas.Orr@scri.com
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- U.T. MD Anderson Cancer Center
-
Hovedetterforsker:
- Timothy Yap, MD
-
Ta kontakt med:
- E-post: TYap@mdanderson.org
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
-
Histologically confirmed, metastatic, or unresectable solid cancer that has either not responded to or progressed during or after appropriate prior systemic anticancer therapy including chemotherapy, immunotherapy, radiation therapy, or appropriate targeted therapy, or for which there is no treatment available or prior SOC therapy was not tolerated and for which there is no further SOC treatment available
-
Part 1: must have one of the following:
- Mesothelioma with or without NF2 mutations
- Advanced solid tumors with NF2 mutations
- Advanced solid tumors with other Hippo pathway mutations or fusions (e.g., FAT1, LATS1/2, YAP fusions; WWTR1-CAMTA1 in EHE).
-
Part 2: must have the tumor histology and oncogenic mutation or genomic aberration specific to each dose expansion cohort defined below:
- Cohort 1: Participants with mesothelioma with or without NF2 mutations
- Cohort 2: Participants with advanced solid tumors with NF2 mutations
- Cohort 3: Participants with advanced solid tumors with other Hippo pathway mutations identified during Part 1 (Phase 1a) dose escalation
- Cohort 4: SW-682 with appropriate combination therapy.
-
In both parts, participants should have known oncogenic mutation identified by Next Generation Sequencing or local assay
-
Must have archival tumor tissue or agree to a fresh tumor biopsy at screening
-
Measurable disease per RECIST 1.1
-
Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
-
Adequate bone marrow, kidney, hepatic, and coagulation function
Key Exclusion Criteria:
- Evidence of symptomatic CNS metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression
- Clinically significant cardiac disease or abnormal cardiac parameters
- Preexistence or inheritance of a familial renal syndrome
- Concomitant non-anti-arrhythmic medications that are known to prolong the QTc interval
- Concomitant medicines that are known strong/moderate inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) and/or CYP1A2 within 14 days or 5 half-lives before the first dose of study treatment
- Concomitant medicines that are known sensitive substrates of CYP3A4, CYP2C19, CYP2D6, CYP1A2, and/or CYP2B6 within 14 days or 5 half-lives before the first dose of study treatment
- Concomitant medicines that are known sensitive substrates of PGP, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, MATE1, MATE2-K, OCT2
- Clinically significant active infection (bacterial, fungal, or viral)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Phase 1 Dose Escalation Cohorts Ranging in Dose
Participants with advanced solid tumors with or without Hippo pathway mutations will receive SW-682 tablets administered orally in continuous 28-day cycles. SW-682 dosage and frequency of administration will vary by cohort. |
SW-682 tablet administered orally |
|
Eksperimentell: Part 2 Dose Expansion Cohort 1
Participants with mesothelioma with or without NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data. |
SW-682 tablet administered orally |
|
Eksperimentell: Part 2 Dose Expansion Cohort 2
Participants with advanced solid tumors with NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data. |
SW-682 tablet administered orally |
|
Eksperimentell: Part 2 Dose Expansion Cohort 3
Participants with advanced solid tumors with other Hippo pathway mutations identified during Part 1 (Phase 1a) dose escalation will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data. |
SW-682 tablet administered orally |
|
Eksperimentell: Part 2 Dose Expansion Cohort 4
Participants will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data, with appropriate combination therapy, identified based on Part 1 data. |
SW-682 tablet administered orally Appropriate combination therapy |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Adverse Events (Part 1 Only)
Tidsramme: Up to 24 months
|
Safety and tolerability endpoint evaluation via incidence of dose limiting toxicities (DLTs), serious adverse events (SAEs), treatment emergent adverse events (TEAE) |
Up to 24 months
|
|
Maximum Tolerated Dose (Part 1 Only)
Tidsramme: Up to 24 months
|
The maximum tolerated dose (MTD) for SW-682, if any, will be based on safety and tolerability during the first 28 days of treatment in Cycle 1. |
Up to 24 months
|
|
Recommended Dose for Expansion (Part 1 Only)
Tidsramme: Up to 24 months
|
The recommended dose for expansion (RDE) will be determined based on all safety, tolerability, pharmacokinetics (PK), preliminary antitumor efficacy, and other available data from Part 1 of the study. |
Up to 24 months
|
|
Objective Response Rate (Part 2 Only)
Tidsramme: Up to 24 months
|
Objective response rate (ORR), defined as the proportion of participants with confirmed CR or PR using RECIST v1.1, mRECIST for mesothelioma, and/or GCIG CA-125 for ovarian cancer, as applicable, assessed by the investigator. |
Up to 24 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in plasma and urine concentrations of SW-682
Tidsramme: Up to 24 months
|
Plasma and urine concentrations of SW-682 and any relevant metabolite(s) will be measured to evaluate systemic exposures and renal elimination. |
Up to 24 months
|
|
Objective Response Rate (Part 1 Only)
Tidsramme: Up to 24 months
|
Objective response rate (ORR), defined as the proportion of participants with confirmed CR or PR using RECIST v1.1, mRECIST for mesothelioma, and/or GCIG CA-125 for ovarian cancer, as applicable, assessed by the investigator. |
Up to 24 months
|
|
Disease Control Rate
Tidsramme: Up to 24 months
|
Disease control rate (DCR), defined as the percentage of participants with CR, PR, or stable disease (SD) after starting study treatment. |
Up to 24 months
|
|
Duration of Response
Tidsramme: Up to 24 months
|
Duration of response (DoR), defined as the time from response (CR + PR using RECIST v1.1, mRECIST and/or (GCIG) criteria for CA-125 response in ovarian cancer, as applicable) to disease progression and/or death, whichever occurs first. |
Up to 24 months
|
|
Progression-Free Survival
Tidsramme: Up to 24 months
|
Progression-free survival (PFS), defined as the time from the date of the first administration of study treatment to the first documented disease progression per RECIST v1.1, mRECIST, and/or GCIG CA-125, as applicable, or death due to any cause, whichever occurs first. |
Up to 24 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studieleder: Medical Responsible, SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdommer i luftveiene
- Neoplasmer etter histologisk type
- Lungesykdommer
- Neoplasmer, kjertel og epitel
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Lungeneoplasmer
- Adenom
- Neoplasmer, mesoteliale
- Pleurale neoplasmer
- Mesothelioma
- Mesothelioma, ondartet
- Terapeutikk
- Kombinert modalitetsterapi
Andre studie-ID-numre
- TEAD-AST-101
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD will not be shared for Phase I interventional or observational studies. Further information on how to request data can be found on our website bit.ly/IPD21.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .